MED DISCOVERY SA
Route de la Corniche 4
1066 Epalinges - Switzerland
Tél +41 21 651 90 76 - Email
Dr DeSerres holds a MD and M.Sc from University of Montreal and a MBA in bioindustries from UQAM. At the beginning of his carreer, he practiced medicine and was Director of teaching unit at McGill University as well as President of the Quebec College of Family Physicians. He has also acted as Director of Public Health in Hull, QC prior to joining Aventis Behring Canada as Medical Director and then as General Manager. He is now VP Clinical Research and Regulatory Affairs at Draximage (a division of Draxis Specialty Pharmaceuticals Inc).
Co-Founder of Med Discovery, graduate of the University of Geneva, Switzerland, he began his Urology training in Professor H.-J. Leisinger's department at the University Hospital CHUV in Lausanne. After spending two years in the Urology department of Idianapolis University in the U.S.A. where he exclusively engaged in research in the field of prostatic carcinoma, he returned to Switzerland to become staff urologist. Dr C. Gygi is member of the American Urology Association and he is involved in different medical boards.
Co-founder of Med Discovery, graduate of the University of Geneva, Switzerland (1979), is associate professor of Urology and Head of the Department of Urology at CHUV-University Hospital in Lausanne Switzerland. He has a special interest in oncologic and reconstructive surgery in Urology with a special interest for bladder cancer and photodynamic applications in this field, in collaboration with the Swiss Federal Institute of Technology (Prof H. van den Bergh). In addition, he is currently involved in basic and clinical research programs. He is member of many scientific societies (AUA, EAU, ESUR, ASLMS, SPIE…).
Dr. Cloutier obtained his Ph.D. in Biochemistry (2002) at Lausanne University. From 2000 to 2002, he was Laboratory Head of the Urology Research Unit at the University Hospital CHUV in Lausanne working on the prostate cancer-specific marker human kallikrein 2 (hK2). Then, as a co-founder and Laboratory Head of Med Discovery, he developed Med Discovery's protease inhibitor technology platform, and using this, the recombinant protease inhibitor MDPK67b, targeting hK2 for the treatment of prostate cancer. Since 2005, he works at Anapharm, a Pharmanet company, located in Canada. Anapharm is a CRO (Clinical Research Organization) Specialized in Clinical development. Dr Cloutier was recently promoted as Clinical Director.
Professor Chagas obtained his Ph.D. in Molecular Biology from the Federal University of São Paulo, Brazil (1991), where he held an Assistant Professor position from 1992. From 1994 to 1996 he also worked as post-doctoral fellow in the University of Tours, France. From 1999 to 2006, as full Professor and Pro-Rector of Research and Graduate Courses in the University of Mogi das Cruzes, São Paulo, Brazil, he was in charge of creating research facilities and graduate courses on Biotechnology and Biomedical Engineering. In 2006 he moved back to the Federal University of São Paulo in its new campus at Santos, a city on the coast of São Paulo State, to participate in the creation of the new Health Sciences facilities, devoted to undergraduate, graduate and research activities.
Dr. Bauer is vice-head of medical oncology at the CHUV. He graduated from the University of Lausanne in 1978. Subsequently he followed training in internal medicine and medical oncology in Geneva and Lausanne. Dr. Bauer is an active member of various medical oncology associations, such as ASCO, ESMO, EORTC, SAKK. He has a special interest in urogenital and gynecologic cancer, and in new drug development.
Professor and Chairman of the Department of Urology at the Inselspital, Bern. Recipient of many awards and research grants, Professor Thalmann is very involved in urological research, with a special interest in onco-urology, and membership in many urological and oncology associations (such as ESUR, EORTC, EAU, AACR, AUA). He is on the editorial and review boards of numerous journals in the field and is in high demand to chair urology meetings throughout Europe. He received his medical training at the University of Bern, and completed post-doctoral research at the University of Texas.